Not independent
Tenure on this board
6.5 yrs
Also a director at
Pulse Biosciences Inc (PLSE)
9 nominees · 4 ballot items.
Stockholders are asked to elect nine directors; ratify PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026; approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers (say-on-pay); and approve an amendment to the 2020 Stock Incentive Plan to add 8,000,000 shares.
To elect nine directors from the nominees named in the Proxy Statement to hold office until the 2027 annual meeting and until their successors are duly elected and qualified.
To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
A non-binding, advisory vote asking stockholders to approve the compensation paid to the Company’s named executive officers, as disclosed in the Executive Compensation section of the Proxy Statement.
This proposal requests an advisory (non-binding) endorsement of the named executive officer (NEO) compensation disclosed in the proxy statement, fulfilling the requirements of Section 14A of the Exchange Act and giving stockholders the opportunity to express their view on pay. Management seeks this advisory approval to confirm stockholder support for its executive pay philosophy, which ties compensation to corporate OKRs, individual performance, and long-term equity incentives. The Compensation Committee highlights that stockholders provided ~97% support for the Company’s say-on-pay in 2025, and it uses the advisory vote as a mechanism to receive feedback while retaining discretion for future pay decisions. Company context: the firm is a development-stage biopharma that links a substantial portion of executive pay to long-term equity and milestone-driven objectives rather than short-term financial metrics. Notably, in 2025 certain performance-based equity awards were modified to remove performance contingencies and become time-based, producing a very large one-time accounting charge that materially increased Summary Compensation Table totals for the year and inflated the apparent single-year compensation of the Co-CEO; management emphasizes that this charge is an accounting re-measurement and not additional cash pay. The Board recommends a FOR vote, arguing compensation aligns executives’ interests with long-term product and regulatory milestones (e.g., BLA filing/acceptance) and retention needs in a competitive talent market. The vote is non-binding, and the Board and Compensation Committee state they will review and consider the voting outcome when making future compensation decisions. Risks and governance considerations include potential stockholder concern over perceived pay-for-performance disconnects driven by the 2025 modification charge and dilution from large equity grants; these are mitigants but remain likely topics for investor engagement. Overall, the proposal is a governance checkpoint rather than a substantive change to compensation structure, and a FOR vote signals approval of the Board’s approach while leaving open active oversight and potential future adjustments.
To approve an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to increase the number of shares authorized for issuance under the Plan by 8,000,000 shares.
This management-sponsored proposal requests shareholder approval to amend the Company’s 2020 Stock Incentive Plan by adding 8,000,000 shares to the reserve available for equity awards. Management argues the increase is necessary to sustain recruiting, retention, and long-term incentive programs, noting that as of April 15, 2026 there were only 11,979,801 shares remaining under the Plan and that the Board already made conditional grants contingent on shareholder approval. The Board framed equity awards as essential to align employee and director incentives with long-term stockholder value, particularly given the Company’s development-stage status and milestone-driven advancement of ivonescimab (including recent BLA submission and FDA acceptance). If the amendment is not approved, the Company warns that conditionally granted options will be terminated for no consideration, creating immediate retention and morale risks. The proposal will produce dilution to existing stockholders; the proxy discloses the total number of options outstanding and other equity plan pools, enabling investors to assess potential dilution and timing of future Form S-8 registration. The Amended Plan contains standard governance protections (e.g., limits on repricing without stockholder approval, change-in-control adjustment provisions, transfer restrictions, and Board-administered grant authority), which somewhat mitigate dilution and governance concerns but do not eliminate the economic effect of newly authorized shares. Management recommends FOR, asserting the benefit of continued access to equity compensation outweighs dilution risks and that the grant authority is necessary to implement competitive long-term incentives. Investors should weigh the Company’s near-term product-development catalysts and retention needs against the incremental share overhang and monitor actual grant pace and post-approval dilution metrics if the amendment is adopted.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 4.69% | 36,391,063 | $690M |
| 2 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.05% | 8,153,895 | $155M |
| 3 | FMR LLC | 0.94% | 7,324,627 | $139M |
| 4 | STATE STREET CORP | 0.91% | 7,028,160 | $133M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 0.74% | 5,711,802 | $108M |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 0.67% | 5,233,252 | $99M |
| 7 | UBS Group AG | 0.47% | 3,612,137 | $68M |
| 8 | BlackRock, Inc. | 0.46% | 3,557,479 | $67M |
| 9 | FMR LLC | 0.45% | 3,528,159 | $67M |
| 10 | BlackRock, Inc. | 0.40% | 3,103,915 | $59M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.